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The active form of vitamin D3, 1,25-dihydroxyvitamin D3, is a major regulator of bone
and calcium homeostasis. In addition, this hormone also inhibits the proliferation and
stimulates the differentiation of normal as well as malignant cells. Supraphysiological
doses of 1,25-dihydroxyvitamin D3 are required to reduce cancer cell proliferation.
However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and
hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin
D3 have been synthesized by the introduction of chemical modifications in the A-ring,
central CD-ring region or side chain of 1,25-dihydroxyvitamin D3 in the hope to find
molecules with a clear dissociation between the beneficial antiproliferative effects and
adverse calcemic side effects. One example of such an analog with a good dissociation
ratio is calcipotriol (Daivonex®), which is clinically used to treat the hyperproliferative skin
disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of
osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used
in the clinic for the treatment of cancer although several analogs have been shown to
be potent drugs in animal models of cancer. Transcriptomics studies as well as in vitro
cell biological experiments unraveled basic mechanisms involved in the antineoplastic
effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D3 and analogs act in a cell
type- and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 toward
S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of
tumor cells together with effects on angiogenesis and inflammation have been implicated
in the pleiotropic effects of 1,25-dihydroxyvitamin D3 and its analogs. In this review we
will give an overview of the action of vitamin D analogs in tumor cells and look forward
how these compounds could be introduced in the clinical practice.
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INTRODUCTION
The active form of vitamin D3, 1,25-dihydroxyvitamin D3
[1α,25(OH)2D3; 1] (Table 1), is mostly known for its effects on
bone, calcium, and phosphate homeostasis. Next to these classi-
cal effects, 1,25(OH)2D3 also exerts so-called non-classical effects
on various tissues which express the vitamin D receptor (VDR)
as well as the enzymes that are responsible for activating the
hydroxylations of vitamin D3, which is essential for the formation
of 1,25(OH)2D3. Thus, most tissues have the ability to convert
vitamin D3 into its active form, 1,25(OH)2D3, which in turn
will bind the VDR in order to positively or negatively influence
target genes via binding of the 1,25(OH)2D3/VDR complex to
vitamin D receptor elements (VDRE). Non-classical properties
of 1,25(OH)2D3 include prodifferentiating and antiproliferative
effects on normal and cancer cells (Colston et al., 1981; Jensen
et al., 2001) as well as immunomodulatory effects. However,
in order to obtain these non-classical effects, 1,25(OH)2D3
doses of the nanomolar range are necessary, while physiological
1,25(OH)2D3 serum concentrations are in the picomolar range.
Since supraphysiological doses of 1,25(OH)2D3 result in hyper-
calcemia, 1,25(OH)2D3 analogs were developed to minimize the
calcemic side effects while preserving or augmenting the benefi-
cial effects of 1,25(OH)2D3. Both industry and academic institu-
tions have synthesized a vast amount of vitamin D analogs. Some
of these analogs have tissue-specific effects with low calcemic side
effects and can be given at higher doses compared to the mother
compound.
CLINICALLY APPROVED VITAMIN D ANALOGS
Given the huge amount of vitamin D analogs that have been
synthesized during the years, it is nearly impossible to give an
overview of them all. In the first part we will discuss vitamin D
analogs that are clinically approved (Table 2). For several con-
ditions such as secondary hyperparathyroidism, psoriasis and
osteoporosis, vitamin D analogs are frequently used as a treat-
ment option. Paricalcitol [2] and doxercalciferol [3] are vitamin
D2 analogs approved for therapeutic use of secondary hyper-
parathyroidism. In Japan falecalcitriol [4] and maxacalcitol [5]
are also used to treat this disease. Secondary hyperparathyroidism
is characterized by elevated parathyroid hormone (PTH) levels in
response to hypocalcemia and is often caused by chronic kidney
disease. Above-mentioned vitamin D analogs suppress PTH, as
does 1,25(OH)2D3, but without inducing severe hypercalcemia.
Clinical studies with chronic kidney disease patients show that
different analogs induce a stronger PTH suppression compared
to placebo treatment (Hamdy et al., 1995; Coburn et al., 2004;
Coyne et al., 2006). Also, end-stage renal disease patients treated
with these analogs often have a better survival (Teng et al., 2003;
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Table 1 | Overview of vitamin D analogs.
Identification Name Structure
number
[1] 1α,25(OH)2D3
OHHO
H
OH
[2] Paricalcitol
(19-nor-1α,25(OH)2D2)
OHHO
H
OH
[3] Doxercalciferol
(1α(OH)D2)
OHHO
H
[4] Falecalcitriol
(26,27 F6-1α,25(OH)2D3)
OHHO
H
CF3
CF3
OH
[5] Maxacalcitol
(22oxa-1α,25(OH)2D3)
OHHO
O
H
OH
[6] Tacalcitol
(1α,24(R)(OH)2D3)
OHHO
H
OH
[7] Calcipotriol
(22-ene-26,27-dehydro-
1α,25(OH)2D3)
OHHO
H
OH
(Continued)
Table 1 | Continued
Identification Name Structure
number
[8] Alfacalcidol
(1α(OH)D3)
OHHO
H
[9] Eldecalcidol
(2β-(3-hydroxypropoxy)-
1α,25(OH)2D3)
H
H
HO
O
OH
OH
O
[10] Seocalcitol
(22,24-diene-24,26,27-
trishomo-1α,25(OH)2D3)
OHHO
H
OH
[11] 20-epi-1α,25(OH)2D3
OHHO
H
OH
[12] Lexicalcitol
(20-epi-22-oxa-24,26,27-
trishomo-1α,25(OH)2D3)
OHHO
H
O
OH
[13] CD578
(17-methyl-19-nor-21-nor-
23-yne-26,27-F6-
1α,25(OH)2D3)
HO OH
OH
CF3
CF3
[14] Inecalcitol
(19-nor-14-epi-23-yne-
1α,25(OH)2D3)
OHHO
H
OH
(Continued)
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Table 1 | Continued
Identification Name Structure
number
[15] TX527
(19-nor-14,20-bisepi-23-
yne-1α,25(OH)2D3)
OHHO
H
OH
[16] 2MD
(2-methylene-19-nor-(20S)-
1α,25(OH)2D3)
OHHO
H
OH
[17] WY1112
(Seco-C-9,11-bisnor-17-
methyl-20-epi-26,27-F6-
1α,25(OH)2D3)
HO OH
CF3
CF3
OH
[18] PRI-2205
((5E,7E)-22-ene-26,27-
dehydro-1α,25(OH)2D3)
OHHO
H
OH
[19] ILX23-7553
(16-ene-23-yne-
1α,25(OH)2D3)
OHHO
H
OH
Tentori et al., 2006; Shinaberger et al., 2008). However, few studies
with chronic kidney disease and end-stage renal disease patients
directly compare the effects of 1,25(OH)2D3 with its analogs.
Psoriasis, a hyperproliferative condition of the skin, is also
treated with vitamin D analogs. Tacalcitol [6], calcipotriol
[7] and the recently approved maxacalcitol [5] are used
either as monotherapy or in combination with topical steroids
such as betamethasone dipropionate to treat psoriasis. The
analogs exert prodifferentiating and antiproliferative effects on
keratinocytes and also possess important anti-inflammatory
properties. Furthermore, alfacalcidol ([1α(OH)D3; 8], actually
a pre-metabolite of 1,25(OH)2D3) and eldecalcitol (ED-71) [9]
are used in Japan in the treatment of osteoporosis. The recently
approved eldecalcitol [9] is more effective than 1,25(OH)2D3
and alfacalcidol [8] in increasing bone mineral density and
mechanical strength in ovariectomized rats (Uchiyama et al.,
2002). Various studies in mouse models as well as in patients
show that treatment with eldecalcitol [9] leads to higher lum-
bar and hip bone mineral density and a lower incidence of
new vertebral fractures (Ito et al., 2011; Matsumoto et al.,
2011; Harada et al., 2012; Hagino et al., 2013), making elde-
calcitol [9] a very promising new analog for the treatment of
osteoporosis.
GENOME- AND TRANSCRIPTOME-WIDE EFFECTS OF
VITAMIN D ANALOGS
The exact mechanism of action of vitamin D analogs still has
to be deciphered. The reason why specific analogs have super-
agonistic actions on specific tissues remains unknown, however
several studies have tried to elucidate the mechanisms behind
these tissue-specific effects. The catabolism of vitamin D analogs
is one of the mechanisms that have an effect on their potency.
Modifications of the side chain of 1,25(OH)2D3 are known to
slow down its catabolism by CYP24A1 (Jones, 1997). Seocalcitol
(EB1089) [10] and 20-epi-1,25(OH)2D3 [11] are degraded slower
compared to 1,25(OH)2D3 leading to a longer exposure of these
analogs to the tissues (Hansen and Maenpaa, 1997; Kissmeyer
et al., 1997; Shankar et al., 1997; Zella et al., 2009). The metabo-
lites formed after catabolism of lexicalcitol [12] are more active
than the ones formed after 1,25(OH)2D3 is catabolized (Dilworth
et al., 1997) and this analog is also more effective in slowing down
the degradation rate of the VDR (van den Bemd et al., 1996).
Moreover, since some cell types prefer specific catabolism path-
ways and enzymes above others, the degradation process may also
contribute to the tissue-specific activity of vitamin D analogs. The
affinity for the vitamin D binding protein (DBP) also plays a role
in the activity of vitamin D analogs. Maxacalcitol [5] for example
has a 500 times lower affinity for DBP and is thus cleared faster
from the circulation than 1,25(OH)2D3 (Okano et al., 1989a).
This analog has a short effect on bone and intestine, tissues
responsible for calcium homeostasis, and a longer effect on PTH
levels, making this analog ideal for the treatment of secondary
hyperparathyroidism. However, it is still unknown why the dura-
tion of the effects is different in these tissues. Eldecalcitol [9] on
the other hand has a higher DBP affinity compared to the mother
compound, leading to longer sustained plasma levels and is thus
more suitable for the treatment of osteoporosis (Okano et al.,
1989b).
Another mechanism that contributes to the superagonistic
effects of vitamin D analogs is their interaction with the VDR,
co-activators and VDREs. 20-epi-1,25(OH)2D3, a C-20 epimer
of 1,25(OH)2D3 [11], promotes heterodimerization between
VDR and retinoid X receptor (RXR) (Liu et al., 2001). 20-epi-
1,25(OH)2D3 [11] and other analogs likemaxacalcitol [5], CD578
[13], inecalcitol [14], and TX527 [15] require lower concen-
trations to recruit specific coactivators to the VDR/RXR/VDRE
complex (Liu et al., 2000; Eelen et al., 2005, 2008; Schwinn and
DeLuca, 2007). Approximately 10- fold lower doses of inecalcitol
[14] and TX527 [15] are needed, compared to 1,25(OH)2D3, to
acquire the same amount of co-activator interactions (Eelen et al.,
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Table 2 | Overview of clinically approved vitamin D analogs.
Name Structure Indication Brand name
Tacalcitol (1α,24(R)(OH)2D3) Psoriasis Curatoderm® (Almirall Hermal),
Bonalfa® (ISDIN, Teijin Pharma),. . .
OHHO
H
OH
Paricalcitol (19-nor-1α,25(OH)2D2) Secondary hyperparathyroidism Zemplar® (Abbott)
OHHO
H
OH
Doxercalciferol (1α(OH)D2) Secondary hyperparathyroidism Hectorol® (Genzyme corp)
OHHO
H
Falecalcitriol (26,27
F6-1α,25(OH)2D3)
Secondary hyperparathyroidism
(Japan only)
Fulstan® (Dainippon Sumitomo)
and Hornel® (Taisho Yakuhin)
OHHO
H
CF3
CF3
OH
Maxacalcitol
(22oxa-1α,25(OH)2D3)
Secondary hyperparathyroidism
and psoriasis (Japan only)
Oxarol® (Chugai Pharmaceutical)
OHHO
O
H
OH
Calcipotriol (22-ene-26,27-
dehydro-1α,25(OH)2D3)
Psoriasis Daivonex®, Dovonex® (LEO
Pharma), Sorilux® (Stiefel)
OHHO
H
OH
Eldecalcitol
(2β-(3-hydroxypropoxy)-
1α,25(OH)2D3)
Osteoporosis (Japan only) Edirol® (Chugai Pharmaceutical)
OHHO
H
O
OH
OH
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2005). Vitamin D analogs might also be able to induce tissue-
specific effects by favoring binding to specific VDRE motifs in
target gene promoters. Analogs with a 20-methyl group as well as
seocalcitol [10] bound to a VDR/RXR complex preferably inter-
act with the IP9 type of VDRE (Danielsson et al., 1996; Quack and
Carlberg, 1999).
On the genome level, studies using chromatin immunopre-
cipitation (ChIP) and micro-array techniques have investigated
1,25(OH)2D3-regulated genes in different cell lines. One ChIP
study compared the binding sites of the VDR in intestinal tissue
after 1,25(OH)2D3 or 20-epi-1,25(OH)2D3 [11] treatment. This
study shows that both 1,25(OH)2D3 and 20-epi-1,25(OH)2D3
[11] induce VDR binding to CYP24A1 and TRPV6 loci in the
intestine, but the analog elicits a prolonged VDR binding to these
genes leading to its superagonistic characteristics such as hyper-
calcemia in vivo (Zella et al., 2009). Other ChIP studies have tried
to investigate the molecular mechanisms of some analogs in dif-
ferent tissues. In osteoblast cell models 2MD [16] bound to the
VDR is able to bind VDREs at lower concentrations compared
to 1,25(OH)2D3 (Yamamoto et al., 2003). Seocalcitol [10], on the
other hand, mediates the dissociation ofWilliams syndrome tran-
scription factor of the aromatase promoter leading to inhibition
of aromatase expression and activity in breast cancer cells which
is one of the main therapeutic strategies in breast cancer patients
(Lundqvist et al., 2013). In a recent paper binding sites of VDR
and mothers against decapentaplegic homolog 3 (SMAD3) were
investigated in hepatic stellar cells. These transforming growth
factor β1 (TGFβ1)-activated cells play an important role in liver
fibrosis. In this study it is shown that VDR and SMAD3 can at
least transiently co-occupy the same genomic sites and function
as enhancers of pro-fibrotic gene expression. However, when cal-
cipotriol [7] is added, the TGFβ1-induced recruitment of SMAD3
is compromised and binding of VDR to these genomic sites is
enhanced 10-foldmeaning that liganded VDR antagonizes SMAD
residency on chromatin and thereby suppresses pro-fibrotic gene
expression (Ding et al., 2013). This genomic feedback circuit is a
previously unknown mechanism of calcipotriol [7].
Micro-array studies in various cancer cell lines such as
leukemia, prostate, breast, colorectal, and ovarian cancer show
that a variety of gene clusters are influenced by 1,25(OH)2D3 and
its analogs (reviewed in Kriebitzsch et al., 2009). Cell growth,
apoptosis, cellular adhesion and extracellular matrix composi-
tion, oxidative stress, immune function, intra- and intercellular
signaling and steroid/lipid metabolism are frequently modulated
processes in cells by 1,25(OH)2D3 and its analogs. However,
when different cell lines are compared, few 1,25(OH)2D3/analog-
regulated genes overlap, which suggests that 1,25(OH)2D3 and its
analogs behave in a cell type- and tissue-specific way. Also stud-
ies using human T-cells (Baeke et al., 2011), rat ventricular heart
tissue (Bae et al., 2011), and bone marrow-derived mouse den-
dritic cells (Griffin et al., 2004) have researched the impact of
1,25(OH)2D3 analogs on gene expression. In these studies genes
important for cell growth, cell death and cell signaling are reg-
ulated, but also a large set of genes implicated in the migration
of T-cells and dendritic cells are influenced. TX527 [15] imprints
human T-cells with amigratory signature and targets them to sites
of inflammation (Baeke et al., 2011). Paricalcitol [2] treatment
of rats with cardiac hypertrophy prevents the progression of car-
diac hypertrophy and the development into chronic heart failure.
The genomic changes associated with cardiac hypertrophy in the
ventricular heart tissue of these rats are, in part, reversed by
paricalcitol [2] administration (Bae et al., 2011). Furthermore,
other studies investigated if 1,25(OH)2D3 analogs are able to bind
and regulate different genes compared to 1,25(OH)2D3. All con-
ducted studies conclude that 1,25(OH)2D3 and its analogs induce
or repress the same set of genes. Seocalcitol [10] induces a less
malignant phenotype in SCC25 squamous cell carcinoma cells
and modulates expression of genes important in cell cycle pro-
gression, cell adhesion, extracellular matrix composition, intra-
and intercellular signaling, G-protein coupled function, redox
balance, and steroid metabolism. In these cells, seocalcitol [10]
regulates the same genes compared to 1,25(OH)2D3, however
gene regulation by 1,25(OH)2D3 is more transient (Lin et al.,
2002). Also WY1112, a seco-9,11-bisnor-17-methyl analog lack-
ing the C-ring and with a 21-epi side chain which is fluorinated
on C26 and C27 [17], was investigated in MCF-7 breast cancer
cells. Despite the 400-fold stronger antiproliferative capacity of
WY1112 [17], the same genes are upregulated after 1,25(OH)2D3
or WY1112 [17] treatment. However, the induction ability is
much higher for the analog (Vanoirbeek et al., 2009). When
treating human coronary artery smooth muscle cells with equal
amounts of 1,25(OH)2D3 or paricalcitol [2] the same genes are
regulated (Wu-Wong et al., 2007; Shalhoub et al., 2010). In con-
clusion, differences in action and capacity of vitamin D analogs
are more due to their specific sensitivities to metabolism and their
specific interaction with the VDR, co-activators and VDREs than
from different gene regulations. However, to our knowledge no
studies have yet looked into the potential differences elicited by
analogs compared to 1,25(OH)2D3 in the fields of proteomics and
epigenetics, which could help to understand the molecular mech-
anism of 1,25(OH)2D3 and its analogs on different cell and tissue
types.
EFFECTS OF VITAMIN D ANALOGS IN CANCER
The use of 1,25(OH)2D3 for the treatment of cancer gained inter-
est since many tissues express vitamin Dmetabolizing enzymes as
well as the VDR and because 1,25(OH)2D3 has potent antipro-
liferative and prodifferentiating effects on normal and malignant
cell lines. Several analogs evaluated in vitro show stronger antipro-
liferative and prodifferentiating effects compared to the mother
compound in different cancer cell lines. These compounds are
further evaluated in rodent models to assess their anti-cancer
activity and safety in vivo. All in vivo studies using rodent cancer
models that were published between 2007 and 2013 are summa-
rized in Table 3. For studies preceding 2007, the reader is referred
to other reviews (Eelen et al., 2007). In most studies the growth
of the tumor is inhibited without inducing severe hypercalcemia
when appropriate doses of vitamin D analogs are used (Abe et al.,
1991; Kawa et al., 1996, 2005; Akhter et al., 1997, Blutt et al.,
2000; Prudencio et al., 2001; Grostern et al., 2002; Flanagan
et al., 2003; Albert et al., 2004a; Wietrzyk et al., 2004; Zhang
et al., 2005; Fichera et al., 2007; van Ginkel et al., 2007; Ghous
et al., 2008; Lee et al., 2008; Schwartz et al., 2008; Gonzalez-
Pardo et al., 2010; Seubwai et al., 2010; Berkovich et al., 2013;
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Table 3 | In vivo studies in rodent cancer models treated with vitamin D analogs (intraperitoneal i.p.; subcutaneous s.c.) published between
2007 and 2013.
Cancer type Dosage vitamin D analog Duration of treatment Outcome References
Seocalcitol (22,24-diene-24,26,27-trishomo-1α,25(OH)2D3)
OHHO
H
OH
Chemically-induced
breast cancer
7μg/kg/week Approximately 80 days Decreased tumor burden and
volume
Liska et al., 2012
Chemically-induced
breast cancer
Oral, 7μg/kg/week 116 or 156 days Prolonged latency of
mammary gland tumors
Macejova et al., 2011
Prostate cancer xenograft i.p., 0.5μg/kg every other day 45 days Reversal of growth
stimulatory effects of PTHrP
Bhatia et al., 2009
Hepatocellular carcinoma
xenograft
Oral and i.p.,
0.02/0.1/0.5μg/kg/d
Approximately 21 days Inhibition of tumor growth Ghous et al., 2008
Inoculation with mice
breast cancer cells
i.p., 20 ng 3×/week 6 weeks Inhibition of tumor growth, no
inhibition of tumor
angiogenesis
Valrance et al., 2007
HY-11 (2-amino-3-deoxy-19-nor-22-ene-26-dihomo-27-dihomo-25(OH)D3)
NH
OH
H
Inoculation with mice
leukemia cells
i.p., 10−5 M/d 26 days 50% increase in survival Yoon et al., 2008
Tacalcitol (1α,24(R)(OH)2D3)
OHHO
H
OH
Inoculation with mice
colorectal cancer cells
Different concentrations s.c.
(3 or 5×/week) or oral
(3×/week) in combination
with different concentrations
of 5-fluorouracil
Variable duration 1μg/kg/d optimal dose +
prolongation of life span of
mice (synergistic effect when
combined with
chemotherapy)
Milczarek et al., 2013a
Inoculation with mice or
human colorectal cancer
cells
s.c., Different concentrations
in combination with different
concentraties of irinotecan or
oxaliplatin
Variable duration Under certain experimental
conditions vitamin D analogs
and chemotherapy can work
synergistically
Milczarek et al., 2013b
(Continued)
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Table 3 | Continued
Cancer type Dosage vitamin D analog Duration of treatment Outcome References
Inecalcitol (19-nor-14-epi-23-yne-1α,25(OH)2D3)
OHHO
H
OH
Squamous cell carcinoma
xenograft
i.p., 80/160/320μg/mouse/d 3 days Inhibition of tumor growth,
increased apoptosis,
decreased proliferation
Ma et al., 2013
Prostate cancer xenograft i.p., 1300μg/kg 3×/week 42 days Delay of tumor growth, 50%
decrease in tumor weight and
decreased tumor vascularity
Okamoto et al., 2012
TX527 (19-nor-14,20-bisepi-23-yne-1α,25(OH)2D3)
OHHO
H
OH
Kaposi sarcoma
xenograft
i.p., 10μg/kg/d 4 days Decreased tumor progression Gonzalez-Pardo et al.,
2010
Paricalcitol (19-nor-1α,25(OH)2D2)
Gastric cancer xenograft s.c., 100 ng/d 3×/week 4 weeks Lower tumor volume,
reduced growth of
intraperitoneal metastasis
Park et al., 2012
Pancreatic cancer
xenograft
s.c., 2.5μg/kg 3×/week Variable duration Inhibition of tumor growth Schwartz et al., 2008
Doxercalciferol (1α(OH)D2)
Neuroblastoma xenograft Oral, 0.15/0.3μg/d 5 weeks Lower tumor volume van Ginkel et al., 2007
(Continued)
www.frontiersin.org April 2014 | Volume 5 | Article 122 | 7
Leyssens et al. The future of vitamin D analogs
Table 3 | Continued
Cancer type Dosage vitamin D analog Duration of treatment Outcome References
Maxacalcitol (22oxa-1α,25(OH)2D3)
Cholangiocarcinoma
xenograft
i.p., 15μg/kg/d 17 days Inhibition of tumor growth Seubwai et al., 2010
Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)2D3)
UV-induced
non-melanoma skin
cancer
Topical application in
combination with diclofenac
and difluoromethylornithine
17 weeks Decrease in number and area
of tumors when combined
with diclofenac
Pommergaard et al., 2013
BGP-13 (1R, 3S, 5Z)-5-((8E)-2-((3R)-3-((2R, 3S)-3-(5-cyclopropyl-3H-1,2-dioxol-3-yl)-2-ethyl-3-methylcyclohexylidene)
ethylidene)-4-methylenecyclohexane-1,3-diol)
OHHO
H
O O
Colorectal cancer
xenograft
i.p., 2μg/kg every 2 days 8 days Inhibition of tumor growth Berkovich et al., 2013
PRI-2205 ((5E,7E)-22-ene-26,27-dehydro-1α,25(OH)2D3)
OHHO
H
OH
Breast and lung cancer
xenograft
s.c., 10μg/kg 2 or 3×/week +
cytostatics
18–21 days Combination of analogs with
low doses of cytostatics is
not effective
Wietrzyk et al., 2007
(Continued)
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Table 3 | Continued
Cancer type Dosage vitamin D analog Duration of treatment Outcome References
PRI-1906 ((24E)-(1S)-24-dehydro-24a-homo-1α,25(OH)2D3)
OHHO
H
OH
Inoculation with mice
breast cancer cells
s.c., 0.1 or 1μg/kg/d 9 or 11 days No effects Wietrzyk et al., 2008
BXL-01-0126 (20R-(4-hydroxy-4-methylpentyl)-23-yne-26,27-hexafluoro-19-nor-1α,25(OH)2D3)
OHHO
H
CF3
OH
CF3HO
Acute myeloid leukemia
xenograft
i.p., 0.0625μg 1 injection Cathelicidin antimicrobial
peptide present in systemic
circulation
Okamoto et al., 2014
BXL0124 (20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-1α,25(OH)2D3)
OHHO
H
H
CF3
OH
CF3HO
D3C
R
D3C
Breast cancer xenograft i.p., 0.1μg/kg or oral
0.03/0.1μg/kg 6 days/week
5 weeks Suppressed tumor growth So et al., 2011
Transgenic mice with
breast cancer
(ErbB2/Her-2/neu
overexpressing tumors)
i.p., 0.3μg/kg 3×/week Approximately 38 weeks Inhibition of tumor growth
and regulation of
ErbB2/AKT/ERK pathway
Lee et al., 2010
Gemini0097 (20R-21(3-trideuteromethyl-3-hydroxy-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-19-nor-1α,25(OH)2D3)
OHHO
H
CD3
CD3
OH
HO
F3C
H
F3C
R
ER-negative breast
cancer xenograft
i.p., 0.1μg/kg/d 9 weeks Suppressed tumor growth Lee et al., 2008
Chemically-induced
breast cancer (ER
positive)
i.p., 0.03/0.1/0.3μg/kg
5days/week
9 weeks Inhibition of tumor burden
(Continued)
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Table 3 | Continued
Cancer type Dosage vitamin D analog Duration of treatment Outcome References
MART-10 (19-nor-2α-(3-hydroxypropyl)-1α,25(OH)2D3)
OHHO
H
OH
H
OH
Pancreatic cancer
xenograft
i.p., 0.3μg/kg 2×/week 3 weeks Inhibition of tumor growth Chiang et al., 2013
1α,25(OH)2D3-3-bromoacetate
OHBCH2COO
H
OH
Kidney cancer xenograft i.p., 0.75μg/kg every third
day
80 days Reduced tumor size and
increased apoptosis
Lambert et al., 2010
Ro26-2198 (16,23Z-diene-26,27-F6-19-nor-1α,25(OH)2D3)
OHHO
H
CF3
CF3
OH
Chemically-induced
colorectal cancer
0.01μg/kg/d via mini-osmotic
pump
28 days Inhibition of dysplasia
progression and inhibition of
proliferation and
pro-inflammatory signals
Fichera et al., 2007
For studies preceding 2007 the reader is referred to other reviews (Eelen et al., 2007).
Chiang et al., 2013). However, in some models the analog dose
that is effective in inhibiting tumor growth also causes hyper-
calcemia and lower survival of the treated animals (Albert et al.,
2004b). Not only tumor proliferation is modulated by vitamin D
analogs, also apoptosis, angiogenesis, migration of tumor cells,
etc. are affected by some analogs. In xenograft studies where
apoptosis in the tumor was investigated after vitamin D ana-
log treatment, apoptosis or the necrotic field in the tumor is
augmented (James et al., 1998; VanWeelden et al., 1998; Hara
et al., 2001; Vegesna et al., 2003; Lambert et al., 2010; Park
et al., 2012). Inecalcitol (Hybrigenics, France) [14] treatment of
mice with squamous cell carcinoma xenografts increases apop-
tosis in the tumors and this increase is higher for the analog
compared to 1,25(OH)2D3, while the capacity of the analog to
inhibit proliferation is equal compared to the mother compound
(Ma et al., 2013). Most studies agree that vitamin D analogs
also have an effect on tumor metastasis. Seocalcitol [10] reverses
the growth-stimulatory effects of parathyroid hormone-related
protein (PTHrP), which plays a major role in prostate cancer pro-
gression and metastasis, in a xenograft mouse model of prostate
cancer. The same study shows that seocalcitol [10] also inhibits
migration and invasion of these prostate cancer cells in vitro
(Bhatia et al., 2009). This analog also reduces the number and
surface area of bone metastasis originating from intracardially
injected breast cancer cells (El Abdaimi et al., 2000). Vitamin D
analogs are thus able to reduce the number and growth of metas-
tasis originating from various types of cancer cells (Sato et al.,
1984; Lokeshwar et al., 1999; Nakagawa et al., 2005; Park et al.,
2012). However, in a study using mice with chemically induced
breast cancer, the invasion capacity of the tumor after seocalcitol
[10] treatment is not affected (Liska et al., 2012). The effect of
vitamin D analogs on angiogenesis has also been studied in vivo,
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but here the results are more conflicting. Some studies show no
effect of vitamin D analogs on angiogenesis (Oades et al., 2002;
Valrance et al., 2007), while others find decreased angiogene-
sis of xenograft tumors. Intraperitoneal injections of inecalcitol
[14] decrease the vascularity of xenografted prostate cancer cells
(Okamoto et al., 2012) and oral treatment of colorectal tumors in
rats with alfacalcidol [8] also inhibits tumor angiogenesis (Iseki
et al., 1999). All in vivo studies conclude that vitamin D analogs
inhibit tumor growth but vitamin D and its analogs often do not
influence tumor number. Seocalcitol [10] was given as chemopre-
vention in a transgenic mouse model for androgen-independent
prostate cancer. Tumor growth is inhibited, however, there is no
prevention in the development of tumors (Perez-Stable et al.,
2002).
Since vitamin D and its analogs do not possess cytostatic
properties, many in vivo studies have focused on vitamin D
analog cancer treatment combined with radiotherapy and/or
chemotherapy.When seocalcitol [10] is combined with radiother-
apy in a xenograft model for breast cancer, the anti-cancer effects
are more effective compared to monotherapy (Sundaram et al.,
2003). Another analog, tacalcitol [6], has been investigated in col-
orectal cancer xenograft in combination with different standard
chemotherapies. Different concentrations as well as administra-
tion routes of tacalcitol [6] or PRI-2205 (an analog of calcipotriol)
[18]were used in combination with different concentrations of 5-
fluorouracil (5-FU). Using specific analog doses and chemother-
apy schedules, a synergistic effect on the prolongation of the life
span of the mice is achieved (Milczarek et al., 2013a). Also the
combination with irinotecan or oxaliplatin was investigated. In
this study the mice also show a longer life span and a stronger
tumor growth inhibition compared to monotherapy when cer-
tain doses of tacalcitol [6] and chemotherapy were used. However,
some combinations were more toxic than the monotherapies
(Milczarek et al., 2013b). Other studies report better effects when
combining calcipotriol [7] and diclofenac in a non-melanoma
skin cancer model (Pommergaard et al., 2013). However, the
combination of vitamin D analogs with chemotherapy does not
always result in additive or synergistic effects. Combining max-
acalcitol [5] and 5-FU did not enhance anti-tumor effects in
a chemically induced breast cancer model (Iino et al., 1992).
Another study investigated calcipotriol [7] and its derivatives in
breast and lung cancer in vivo models and concluded that these
analogs and low dose cytostatics are not effective in the used
models (Wietrzyk et al., 2007). Also tacalcitol [6] in combination
with cyclophosphamide does not lead to a significant difference
in tumor growth inhibition compared to the vehicle treatment
(Wietrzyk et al., 2008).
In view of the promising results that certain vitamin D analogs
show against cancer in vitro and in vivo animal models, some
analogs have been tested in cancer patients (Table 4). Seocalcitol
[10] is an analog that has been extensively studied in vitro and
in vivo in different cancer models, however in clinical trials the
results are rather disappointing. Patients with advanced breast
or colon cancer were treated with different doses of seocalcitol
[10] (most patients tolerate 7μg/d) but none of them showed
a complete or partial response (Gulliford et al., 1998). Also oral
seocalcitol [10] treatment in patients with inoperable pancreatic
cancer exhibited no objective anti-tumor activity (Evans et al.,
2002). Two out of 33 patients with inoperable hepatocellular car-
cinoma showed a complete response after oral seocalcitol [10]
treatment, however the majority of the patients presented sta-
ble or progressive disease (Dalhoff et al., 2003). Inecalcitol [14]
is in an early stage II of its clinical trial in chronic lympho-
cytic leukemia. Fifteen patients received 2mg/d orally and one
patient had a 90% decrease in blood lymphocyte count after 10
months of treatment, in 8 other patients blood lymphocyte count
stopped growing when the treatment started (Hybrigenics, 2014).
Intravenous administration of paricalcitol [2], an analog that
is approved for secondary hyperparathyroidism, also displayed
no objective responses in patients with androgen-independent
prostate cancer. However, elevated serum PTH levels, which are
common for advanced prostate cancers, are reduced by the analog
(Schwartz et al., 2005). Doxercalciferol [3], also used in the treat-
ment against secondary hyperparathyroidism, was investigated in
androgen-independent prostate cancer patients. A phase I study
administered oral doxercalciferol [3] between 5 and 15μg/d,
which was well tolerated by the patients (Liu et al., 2002). In
the following phase II study, patients were treated with 12.5μg/d
for a minimum of 8 weeks and 30% of these patients experi-
enced stable disease for over 6 months (Liu et al., 2003). Oral
treatment of non-Hodgkin’s lymphoma patients with 1μg/d alfa-
calcidol [8], a pre-metabolite of 1,25(OH)2D3, resulted in a low
overall response. Out of 34 treated patients, only 4 had a com-
plete response and 4 others showed a partial response to the
treatment (Raina et al., 1991). Calcipotriol [7] is often used to
treat skin psoriasis and has thus been investigated in patients
with locally advanced or cutaneous metastases from breast can-
cer. In both studies the analog was applied topically at a dose
of 100μg/d. One study reported no response after 3 months
of treatment (O’Brien et al., 1993), while in the other study
3 patients showed a 50% reduction in the diameter of treated
lesions after 6 weeks (Bower et al., 1991). A more recently devel-
oped analog, ILX23-7553 [19], was investigated in 16 patients
with advanced solid tumors but no objective response was seen
(Jain et al., 2011). Similar to the in vivo studies, clinical trials
have also combined vitamin D analogs with standard radiother-
apy or chemotherapy.Metastatic breast cancer patients were given
oral paricalcitol [2] doses between 2 and 7μg/d in combination
with taxane-based chemotherapy and this regimen was well tol-
erated by the patients (Lawrence et al., 2013). Oral inecalcitol
[14] was given to patients with hormone-refractory prostate can-
cer in combination with docetaxel for maximum 18 weeks. This
study had a response rate of 85% based on a PSA decline of at
least 30% within 3 months of treatment (Hybrigenics, 2014). In
a small study with acute non-lymphoid leukemia patients the
combination of alfacalcidol [8] and chemotherapy resulted in
17% of the patients with a complete response and 45% with a
partial response (Petrini et al., 1991). The same analog was com-
bined with standard treatment of surgery, radiotherapy, and/or
chemotherapy in glioblastoma and anaplastic astrocytomas. Here,
0.04μg/kg/d alfacalcidol [8] was administered resulting in 27%
of the patients with progressive regression of the lesion and com-
plete clinical remission (Trouillas et al., 2001). In metastatic renal
cell carcinoma patients, oral treatment of 1μg alfacalcidol/d [8]
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Table 4 | Clinical trials with vitamin D analog supplementation.
Cancer type Sample
size
Dosage vitamin D
analog
Duration of
treatment
Outcome References
Seocalcitol (22,24-diene-24,26,27-trishomo-1α,25(OH)2D3)
OHHO
H
OH
Inoperable
hepatocellular
carcinoma
33 Oral individual dosage,
most patients tolerate
10μg/d
Up to 1 year 2 patients with complete response;
12 with stable disease; 19 with
progressive disease
Dalhoff et al., 2003
(uncontrolled trial)
Inoperable
pancreatic cancer
36 Oral individual dosage,
most patients tolerate
10–15μg/d
Minimum 8 weeks No objective anti-tumor activity Evans et al., 2002
(uncontrolled trial)
Advanced breast
cancer and colorectal
cancer
36 Individual dosage
(solution), most patients
tolerate 7μg/d
From 5 days up to 1
year
No complete or partial responses Gulliford et al., 1998
(uncontrolled trial)
Inecalcitol (19-nor-14-epi-23-yne-1α,25(OH)2D3)
OHHO
H
OH
Hormone-refractory
prostate cancer
54 Oral individual dosage,
maximum tolerated dose
is 4 mg/d + docetaxel
(chemotherapy)
Maximum 18 weeks 85% response rate based on a PSA
decline of at least 30% within 3
months
Hybrigenics, 2014
(uncontrolled trial)
Chronic lymphocytic
leukemia
15 Oral 2 mg/d Not found 1 patient had a 90% decrease in blood
lymphocyte count after 10 months of
treatment; in 8 patients blood
lymphocyte count stopped increasing
when treatment was started; 6
patients showed no response
Hybrigenics, 2014
(uncontrolled trial)
Paricalcitol (19-nor-1α,25(OH)2D2)
OHHO
H
OH
Metastatic breast
cancer
24 Oral individual dosage,
2–7μg/d + taxane-based
chemotherapy
8 weeks Well tolerated regimen Lawrence et al., 2013
(uncontrolled)
(Continued)
Frontiers in Physiology | Integrative Physiology April 2014 | Volume 5 | Article 122 | 12
Leyssens et al. The future of vitamin D analogs
Table 4 | Continued
Cancer type Sample
size
Dosage vitamin D
analog
Duration of
treatment
Outcome References
Androgen-
independent
prostate cancer
18 i.v., Individual dosage,
3×/week 5–25μg
Up to 12 weeks No objective response, reduced
serum PTH levels
Schwartz et al., 2005
(uncontrolled)
Doxercalciferol (1α(OH)D2)
OHHO
H
Localized prostate
cancer and high
grade prostatic
intraepithelial
neoplasia
31 Oral, 10μg/d 4 weeks No beneficial effects in serum and
tissue markers
Gee et al., 2013
(placebo-controlled)
Metastatic
androgen-
independent
prostate cancer
70 Oral, 10μg/d + docetaxel 4 weeks No enhanced PSA response rate or
survival
Attia et al., 2008
(placebo-controlled)
Advanced androgen-
independent
prostate cancer
26 Oral, 12.5μg/d Minimum 8 weeks 30% experienced stable disease for
over 6 months
Liu et al., 2003
(uncontrolled)
Advanced androgen-
independent
prostate cancer
25 Oral individual dosage,
5–15μg/d
Minimum 8 weeks Well tolerated, maximal tolerated
dose was not reached
Liu et al., 2002
(uncontrolled)
Alfacalcidol (1α(OH)D3)
OHHO
H
Metastatic renal cell
carcinoma
16 Oral, 1μg/d +
interferon-α (3×/week)
Minimum 3 months 25% had partial response Obara et al., 2008
(uncontrolled)
Glioblastoma and
anaplastic
astrocytomas
11 0.04μg/kg/d +
surgery/chemotherapy/
radiotherapy
Not found 27% showed progressive regression
of the lesion and had a complete
clinical remission
Trouillas et al., 2001
(uncontrolled)
Myelodysplastic
syndromes
30 Oral, 4–6μg/d Median 17 months Prolongation of leukemic
transformation-free survival
Motomura et al.,
1991
(placebo-controlled)
Acute non-lymphoid
leukemia
11 Analog + chemotherapy Not found 17% complete remission, 45% partial
remission
Petrini et al., 1991
(uncontrolled)
Progressive
low-grade
non-Hodgkin’s
lymphoma
34 Oral, 1μg/d Minimum 8 weeks 4 patients has a complete response, 4
other patients had a partial response
Raina et al., 1991
(uncontrolled)
(Continued)
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Table 4 | Continued
Cancer type Sample
size
Dosage vitamin D
analog
Duration of
treatment
Outcome References
Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)2D3)
OHHO
H
OH
Locally advanced or
cutaneous
metastatic breast
cancer
19 Topical 100μg/d 6 weeks 3 patients showed 50% reduction in
diameter of treated lesions
Bower et al., 1991
(uncontrolled)
Locally advanced or
cutaneous
metastatic breast
cancer
15 Topical 100μg/d 3 months No response O’Brien et al., 1993
(uncontrolled)
ILX23-7553 (16-ene-23-yne-1α,25(OH)2D3)
OHHO
H
OH
Advanced solid
tumors
16 Oral individual dosage,
1.7–37.3μg/m2/d for 3
consecutive days,
repeated in 7-day cycle
Minimum 3 weeks No objective response Jain et al., 2011
(uncontrolled)
was combined with a 3 weekly administration of interferon-α for
minimal 3 months. In these patients 25% had a partial response
to the combination therapy (Obara et al., 2008). Randomized,
placebo-controlled studies have been conducted with oral doxer-
calciferol [3] or alfacalcidol [8]. One study administered 10μg/d
doxercalciferol [3] or placebo during 4 weeks to patients with
localized prostate cancer or high-grade prostatic intraepithelial
neoplasia. However, no beneficial effects in serum or tissue mark-
ers were seen (Gee et al., 2013). Another study used the same dose
in metastatic androgen-independent prostate cancer patients but
combined the treatment with docetaxel. Also here, no enhanced
PSA response rate or survival rate was seen after 4 weeks of
treatment (Attia et al., 2008). Oral alfacalcidol [8] or placebo
was given to patients with myelodysplastic syndromes. In the
patients treated with the analog, a prolongation of leukemic
transformation-free survival was seen compared to the placebo
group (Motomura et al., 1991). Despite the promising in vitro
and in vivo results of vitamin D analogs in cancer models, clin-
ical trials have failed to proof the effects of vitamin D analogs in
cancer patients. Vitamin D and its analogs lack cytotoxic activity,
so using these analogs in combination with standard therapies
such as radio- and chemotherapy is probably more effective than
using the analogs as monotherapy. Next to the combination of
analogs with standard cancer therapies, it is also possible that
these analogs need to be given for a longer period of time or that
treatment with analogs has to be started earlier, for example in
early stages of disease or even as chemoprevention.
CONCLUSIONS AND PERSPECTIVES
Vitamin D and its analogs exhibit strong antiproliferative and
prodifferentiating effects on different normal and malignant cell
types. Several vitamin D analogs have been approved for treating
psoriasis, osteoporosis, and secondary hyperparathyroidism and
are often used as first or second-line treatment option. Despite
promising in vitro as well as in vivo results in various cancer
models, vitamin D analog treatment in clinical trials with cancer
patients failed to prove efficacy in most trials. Different combina-
tions of analogs and standard cancer therapies should be further
explored as well as the correct duration and timing of adminis-
tration. To unravel the exact working mechanisms of vitamin D
analogs more research studies should compare the effects of vita-
min D analogs in different cell types to the mother compound.
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Furthermore, differences between 1,25(OH)2D3 and its analogs
are probably more due to their differences in metabolism and
coactivator recruitment than from different genetic regulations.
However, some fields such as epigenetics and proteomics remain
largely unexplored in comparing the potentially distinctive effects
of 1,25(OH)2D3 and its analogs. Since all current genomic and
transcriptomic studies focus on established human cell lines,
micro-array, and ChIP techniques comparing the effects of
1,25(OH)2D3 and its analogs on human primary tumor tissues
should be investigated in the future.
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